{"id":"daratumumab-darzalex","safety":{"commonSideEffects":[{"rate":"48","effect":"Infusion-related reactions"},{"rate":"35","effect":"Fatigue"},{"rate":"25","effect":"Nausea"},{"rate":"20","effect":"Fever"},{"rate":"18","effect":"Cough"},{"rate":"35","effect":"Neutropenia"},{"rate":"25","effect":"Anemia"},{"rate":"15","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL1743007","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Daratumumab targets CD38, a surface antigen highly expressed on malignant plasma cells in multiple myeloma. Upon binding, it induces cell death through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). This multi-modal mechanism makes it effective in both newly diagnosed and relapsed/refractory multiple myeloma.","oneSentence":"Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:40.743Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed)"},{"name":"Multiple myeloma (relapsed or refractory)"},{"name":"Light chain multiple myeloma"}]},"trialDetails":[{"nctId":"NCT07222761","phase":"PHASE3","title":"A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-01-02","conditions":"Relapsed and/or Refractory Multiple Myeloma (RRMM)","enrollment":915},{"nctId":"NCT07477587","phase":"PHASE1","title":"A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-05-27","conditions":"Multiple Myeloma (MM)","enrollment":258},{"nctId":"NCT07393282","phase":"PHASE3","title":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-25","conditions":"High Risk Smoldering Multiple Myeloma (HR-SMM)","enrollment":270},{"nctId":"NCT05807048","phase":"PHASE2","title":"Daratumumab in STK11 Mutated NSCLC","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-06-01","conditions":"Non-small Cell Lung Cancer With STK11/LKB1 Mutation","enrollment":8},{"nctId":"NCT07428369","phase":"PHASE2, PHASE3","title":"A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-06-05","conditions":"Multiple Myeloma (MM)","enrollment":1570},{"nctId":"NCT03275285","phase":"PHASE3","title":"Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-10-25","conditions":"Plasma Cell Myeloma","enrollment":302},{"nctId":"NCT05137054","phase":"PHASE1","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-17","conditions":"Multiple Myeloma","enrollment":317},{"nctId":"NCT04827979","phase":"PHASE1, PHASE2","title":"Daratumumab and Belatacept for Desensitization","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-01","conditions":"Highly Sensitized Prospective Kidney Transplant Recipients","enrollment":19},{"nctId":"NCT04824794","phase":"PHASE1, PHASE2","title":"GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies","status":"TERMINATED","sponsor":"Genmab","startDate":"2021-03-09","conditions":"Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)","enrollment":130},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT07285239","phase":"PHASE3","title":"Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":500},{"nctId":"NCT07274462","phase":"PHASE4","title":"DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Martin","startDate":"2025-11-01","conditions":"Microvascular Inflammation - MVI in Kindey Transplant Recipients","enrollment":20},{"nctId":"NCT02970747","phase":"","title":"Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2016-10-25","conditions":"Multiple Myeloma in Relapse","enrollment":359},{"nctId":"NCT05300451","phase":"PHASE2","title":"Daratumumab in HLA Desensitization Prior to Transplantation","status":"ENROLLING_BY_INVITATION","sponsor":"Barry A. Boilson","startDate":"2022-03-31","conditions":"Cardiac Transplant","enrollment":10},{"nctId":"NCT03500445","phase":"PHASE2","title":"Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-02-13","conditions":"Myeloma, Multiple Myeloma","enrollment":75},{"nctId":"NCT04045795","phase":"PHASE1","title":"Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Multiple Myeloma","enrollment":56},{"nctId":"NCT07085728","phase":"PHASE2","title":"Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure","status":"NOT_YET_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2025-08-11","conditions":"Myeloma Multiple","enrollment":74},{"nctId":"NCT04643002","phase":"PHASE1, PHASE2","title":"Isatuximab in Combination With Novel Agents in RRMM - Master Protocol","status":"RECRUITING","sponsor":"Sanofi","startDate":"2021-01-25","conditions":"Plasma Cell Myeloma Refractory","enrollment":258},{"nctId":"NCT07110662","phase":"PHASE1, PHASE2","title":"New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-10-29","conditions":"Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)","enrollment":9},{"nctId":"NCT05671757","phase":"PHASE1, PHASE2","title":"Daratumumab in Primary Antiphospholipid Syndrome","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-05-26","conditions":"Autoimmune Disorders","enrollment":22},{"nctId":"NCT06918002","phase":"PHASE3","title":"Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients","status":"RECRUITING","sponsor":"Intergroupe Francophone du Myelome","startDate":"2025-07-09","conditions":"Multiple Myeloma, Newly Diagnosed","enrollment":824},{"nctId":"NCT03158688","phase":"PHASE3","title":"Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-06-13","conditions":"Relapsed Multiple Myeloma, Refractory Multiple Myeloma","enrollment":466},{"nctId":"NCT06895512","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":386},{"nctId":"NCT04972942","phase":"PHASE1","title":"Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2023-05-22","conditions":"T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma","enrollment":30},{"nctId":"NCT06371534","phase":"PHASE1","title":"A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-04-12","conditions":"Tumor","enrollment":228},{"nctId":"NCT06742138","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-01","conditions":"Multiple Myeloma","enrollment":284},{"nctId":"NCT03319667","phase":"PHASE3","title":"A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2017-12-07","conditions":"Plasma Cell Myeloma","enrollment":475},{"nctId":"NCT05679258","phase":"PHASE1","title":"A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2023-01-31","conditions":"Multiple Myeloma","enrollment":172},{"nctId":"NCT06232707","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"WITHDRAWN","sponsor":"Celgene","startDate":"2024-05-03","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT05749276","phase":"PHASE1","title":"Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-05","conditions":"Adult Patients With Adverse Risk Acute Myeloblastic Leukemia","enrollment":12},{"nctId":"NCT06296121","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Biocad","startDate":"2023-12-21","conditions":"Multiple Myeloma","enrollment":252},{"nctId":"NCT05974969","phase":"PHASE1","title":"A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects","status":"COMPLETED","sponsor":"Biocad","startDate":"2023-05-17","conditions":"Healthy","enrollment":146},{"nctId":"NCT03637764","phase":"PHASE1, PHASE2","title":"Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-08-06","conditions":"Neoplasm","enrollment":107},{"nctId":"NCT04136756","phase":"PHASE1","title":"NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2019-10-07","conditions":"Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT03221634","phase":"PHASE2","title":"Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-08-01","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT00574288","phase":"PHASE2","title":"Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2008-03-26","conditions":"Multiple Myeloma","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Experimental: Daratumumab (Darzalex®)"],"phase":"marketed","status":"active","brandName":"DARATUMUMAB (DARZALEX®)","genericName":"DARATUMUMAB (DARZALEX®)","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms. Used for Multiple myeloma (newly diagnosed), Multiple myeloma (relapsed or refractory), Light chain multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}